On April 4, 2024 Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing targeted therapies for patients with RAS-addicted cancers, reported that Mark A. Goldsmith, M.D., Ph.D., the company’s chief executive officer and chairman, will be a featured speaker at the 23rd Annual Needham Healthcare Conference and the Stifel Targeted Oncology Forum (Press release, Revolution Medicines, APR 4, 2024, View Source [SID1234641787]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Details of the company’s participation are as follows:

23rd Annual Needham Healthcare Conference
Conference Dates: April 8-11, 2024
Fireside Chat Time/Date: 1:30 – 2:10 p.m. ET on Thursday, April 11, 2024
Location: Virtual; webcast available
Stifel Targeted Oncology Forum
Conference Dates: April 16-17, 2024
Fireside Chat Time/Date: 3:30 – 3:55 p.m. ET on Tuesday, April 16, 2024
Location: Virtual; webcast available

To access the live webcasts of the Needham and Stifel fireside chats, please visit the "Events & Presentations" page of Revolution Medicines’ website at View Source Additionally, a replay of each webcast will be available on the "Events & Presentations" page of the Revolution Medicines website for at least 14 days following the conference.